PFIC Treatment Methods Using IBAT Inhibitor Odevixibat
Summary
USPTO published patent application US20260091040A1 for methods of treating progressive familial intrahepatic cholestasis (PFIC) using IBAT inhibitor odevixibat. Inventors include Per-Göran Gillberg, Jan Mattsson, Pat Horn, and Paresh Soni. The application covers reducing pruritus scores, serum bile acid concentration, improving liver parameters, height normalization, weight improvement, and sleep quality.
What changed
USPTO published patent application US20260091040A1 on April 2, 2026, covering methods for treating progressive familial intrahepatic cholestasis (PFIC) with ileal bile acid transport (IBAT) inhibitor odevixibat or its pharmaceutically acceptable salts. The application (No. 19334510, filed September 19, 2025) claims methods including reducing mean pruritus score, reducing mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.
This is a patent application publication, not a granted patent or regulatory requirement. Pharmaceutical companies and researchers developing PFIC treatments should review the claims for potential freedom-to-operate concerns or licensing opportunities. No compliance actions or deadlines are associated with this document.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Treating Progressive Familial Intrahepatic Cholestasis (PFIC) with IBAT Inhibitors
Application US20260091040A1 Kind: A1 Apr 02, 2026
Inventors
Per-Göran GILLBERG, Jan MATTSSON, Pat HORN, Paresh SONI
Abstract
Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.
CPC Classifications
A61K 31/554 A61K 9/1652 A61K 9/1676 A61P 1/16
Filing Date
2025-09-19
Application No.
19334510
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.